GALECTIN THERAPEUTICS INC. (NASDAQ:GALT) Files An 8-K Other Events

GALECTIN THERAPEUTICS INC. (NASDAQ:GALT) Files An 8-K Other Events
Item 8.01

On June 30, 2020, the Company issued the press release attached hereto as Exhibit 99.1.

SECTION 9 – FINANCIAL STATEMENTS AND EXHIBITS

99.1    Press release

-2-

Story continues below


GALECTIN THERAPEUTICS INC Exhibit
EX-99.1 2 d89121dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   Galectin Therapeutics Announces Commencement of patient enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis Clinical Trial for patients with NASH cirrhosis who have the highest need for effective therapy Belapectin has previously shown ability to prevent the development of esophageal varices in this patient population Compelling NASH-RX trial result could potentially lead to accelerated FDA approval and/or partnership opportunities and fulfill an acute unmet medical need NORCROSS,…
To view the full exhibit click here

About GALECTIN THERAPEUTICS INC. (NASDAQ:GALT)

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company’s galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.

An ad to help with our costs